自体免疫疾病合作与授权交易（2016-2024）

本报告审查了2016年至2024年期间与自体免疫疾病相关的905 份合作和授权交易，并审查了交易总数、财务交易条款以及交易活跃的前25 家公司的趋势。

本报告涵盖以下自体免疫疾病：

• 多发性硬化症、不宁腿症候群、皮肤炎、湿疹、掉髮、牛皮癣、乳糜泻、发炎性肠道疾病、克隆氏症、溃疡性结肠炎、肾丝球肾炎、子宫内膜异位症、免疫系统血小板减少性紫斑症、嗜中性白血球减少症、移植物抗宿主疾病、硬皮症、系统性红斑狼疮、爱迪生氏病、第一型糖尿病、僵直性脊椎炎、幼年关节炎、干癣性关节炎、类风湿性关节炎、小径发炎、发作性睡病、慢性阻塞性肺病、特发性肺纤维化、结节性多发性动脉炎、梅尼尔氏症等。

主な利点

本报告为读者提供了以下主要好处：

• 了解2016年以来的合约趋势
• 查看业务伙伴交易
• 基准分析：确定交易的市场价值
• 财务条件
• 交易清单：依公司名称（A-Z）、治疗领域和技术类型
• 主要交易（金额基础）
• 最活跃的谈判者
• 每笔交易的资产识别和交易条件
• 取得合约文件：深入了解交易结构
• 实质审查：评估拟议交易条款对合作伙伴公司的适用性
• 节省数百小时的研究时间

合约分析允许实质审查：

• 授予/选择了哪些权利？
• 合约授予了哪些权利？
• 授予哪些类型的专有权？
• 合约的付款结构为
• 如何审核销售和付款？
• 合约期限为
• 合约的主要条款是如何定义的？
• 如何对待和拥有知识产权？
• 谁负责商业化？
• 谁负责开发、供应和製造？
• 如何管理保密和发布？
• 如何解决争议？
• 什么情况下可以取消合约？
• 如果所有者发生变化会怎样？
• 已就哪些从属许可或分包条款达成协议？
• 公司需要哪些样板条款？
• 哪些样板条款看起来有所不同，取决于合作伙伴和交易类型？
• 每家公司对合约法拥有哪些管辖权？

目次

执行摘要

第1章 简介

第2章 自体免疫疾病贸易趋势

• 自体免疫疾病相关交易：年度趋势
• 自体免疫疾病相关交易：依交易类型
• 自体免疫疾病相关交易：依行业分类
• 自体免疫疾病相关交易：依发展阶段
• 自体免疫疾病相关交易：依技术类型

第3章 自体免疫疾病：金融交易条款

• 财务条款的揭露
• 标题金额
• 预付款
• 里程碑
• 特许权使用费率

第4章 自体免疫疾病：主要客户与交易

• 交易中最活跃的谈判者
• 最活跃的交易谈判者名单
• 主要交易：依交易金额

第5章 自体免疫疾病交易：合约文件目录

• 合约文件：可用

第6章 自己免疫疾患取引：治疗标的别

• 自体免疫疾病交易：依治疗目标分类
• 交易目录
• 交易目录：依公司（2016-2024年）
• 贸易名录：依技术类型（2016-2024年）
• 交易类型的定义
• 关于Biopharma Research Ltd
• 目前的合作关係
• 当前合约
• Current Partnering 最近的报告标题

Autoimmune Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the autoimmune deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 905 autoimmune deals from 2016 to 2024.

The report includes coverage of the following autoimmune diseases:

• Multiple sclerosis, Restless leg syndrome, Dermatitis, Eczema, Alopecia, Psoriasis, Celiac disease, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Glomerulonephritis, Endometriosis, Immune thrombocytopenic purpura, Neutropenia, Graft versus host disease, Scleroderma, Systemic lupus erythematosus, Addison's disease, Diabetes Type 1, Ankylosing spondylitis, Juvenile arthritis, Psoriatic arthritis, Rheumatoid arthritis, Uveitis, Narcolepsy, Chronic obstructive pulmonary disease, Idiopathic pulmonary fibrosis, Sarcoidosis, Meniere's disease, and other autoimmune disorders.
• The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
• Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
• This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
• The initial chapters of this report provide an orientation of autoimmune dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in autoimmune dealmaking.
• Chapter 3 covers the financial deal terms for deals signed in the autoimmune field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
• Chapter 4 provides a review of the top 25 most active biopharma companies in autoimmune dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
• Chapter 5 provides a comprehensive and detailed review of autoimmune deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
• Chapter 6 provides a comprehensive directory of autoimmune deals listed by theraeutic target.
• The report also includes numerous table and figures that illustrate the trends and activities in autoimmune deal making since 2016.
• In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Autoimmune Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse autoimmune collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Autoimmune Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of autoimmune trends and structure of deals entered into by leading biopharma companies worldwide.

Autoimmune Collaboration and Licensing Deals includes:

• Trends in autoimmune dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of autoimmune deal records covering pharmaceutical and biotechnology
• The leading autoimmune deals by value
• Most active autoimmune licensing dealmakers

In Autoimmune Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Autoimmune Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in autoimmune dealmaking

• 2.1. Introduction
• 2.2. Autoimmune deals over the years
• 2.3. Autoimmune deals by deal type
• 2.4. Autoimmune deals by industry sector
• 2.5. Autoimmune deals by stage of development
• 2.6. Autoimmune deals by technology type

Chapter 3 - Financial deal terms for autoimmune deals

• 3.1. Introduction
• 3.2. Disclosed financials terms for autoimmune deals
• 3.3. Autoimmune deal headline values
• 3.4. Autoimmune deal upfront payments
• 3.5. Autoimmune deal milestone payments
• 3.6. Autoimmune deal royalty rates

Chapter 4 - Leading autoimmune dealmakers and deals

• 4.1. Introduction
• 4.2. Most active in autoimmune dealmaking
• 4.3. List of most active dealmakers in autoimmune
• 4.4. Top autoimmune deals by value

Chapter 5 - Autoimmune deal contract document directory

• 5.1. Introduction
• 5.2. Autoimmune partnering deals where contract document available

Chapter 6 - Autoimmune dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by autoimmune therapeutic target
• Deal Directory
• Deal Directory - Autoimmune deals by company A-Z 2016 to 2024
• Deal Directory - Autoimmune deals by technology type 2016 to 2024
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Autoimmune deals since 2016
• Figure 2: Autoimmune deals by deal type since 2016
• Figure 3: Autoimmune deals by industry sector since 2016
• Figure 4: Autoimmune deals by stage of development since 2016
• Figure 5: Autoimmune deals by technology type since 2016
• Figure 6: Autoimmune deals with a headline value
• Figure 7: Autoimmune deals with upfront payment values
• Figure 8: Autoimmune deals with milestone payment
• Figure 9: Autoimmune deals with royalty rates
• Figure 10: Active autoimmune dealmaking activity since 2016
• Figure 11: Top autoimmune deals by value since 2016